Title:
【発明の名称】CD45阻害剤
Document Type and Number:
Japanese Patent JP2003518040
Kind Code:
A
Abstract:
Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q<1> at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q<2> is selected from hydrogen, halogen, O-(C1-C3)alkyl, O-(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.
More Like This:
Inventors:
Chap de line, mark jerome
Knappen Burger, Catherine
Steelman, Gary
Scad, Suzanne
Seagowski, Linda
Urbaneck, Rebecca
Weare, Chris Alan
Knappen Burger, Catherine
Steelman, Gary
Scad, Suzanne
Seagowski, Linda
Urbaneck, Rebecca
Weare, Chris Alan
Application Number:
JP2001546420A
Publication Date:
June 03, 2003
Filing Date:
December 18, 2000
Export Citation:
Assignee:
AstraZeneca Activrag
International Classes:
A61K31/122; A61K31/235; A61P37/02; A61P37/06; A61P43/00; C07C46/00; A61K31/404; C07C50/24; C07C69/95; C07C205/46; C07D209/08; (IPC1-7): A61K31/122; A61K31/235; A61K31/404; A61P37/02; A61P43/00; C07D209/08
Attorney, Agent or Firm:
Kazuo Shamoto (5 outside)